中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 11
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(11): 2510-2514

Epidemiology of drug-induced liver injury

DOI: 10.3969/j.issn.1001-5256.2021.11.002

  • Shanghai Research Center for Diagnosis and Treatment of Fatty Liver Disease, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China

Research funding:

Clinical Research Innovation Cultivation Fund of Renji hospital, Shanghai Jiao Tong University School of Medicine (PYI20-05)

  • Received Date: 2021-08-31
  • Accepted Date: 2021-08-31
  • Published Date: 2021-11-20
    Abstract
  • The incidence rate of drug-induced liver injury (DILI) is increasing year by year, and DILI has become one of the common liver diseases in clinical practice and has attracted the attention of the whole world. It is known that a variety of drugs, including Chinese herbal medicine and dietary supplements, can cause various types of acute or chronic liver injury, and acute liver failure may occur in severe cases, leading to death or liver transplantation. This article elaborates on the global prevalence of DILI and the distribution of common suspected drugs.

     

    • FullText(HTML)
  • loading
    • References(43)
  • [1]
    CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966; quiz 967. DOI: 10.1038/ajg.2014.131.
    [2]
    ANDRADE RJ, CHALASANI N, BJÖRNSSON ES, et al. Drug-induced liver injury[J]. Nat Rev Dis Primers, 2019, 5(1): 58. DOI: 10.1038/s41572-019-0105-0.
    [3]
    Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [4]
    BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425, 1425. e1-3; quiz e19-20. DOI: 10.1053/j.gastro.2013.02.006.
    [5]
    SGRO C, CLINARD F, OUAZIR K, et al. Incidence of drug-induced hepatic injuries: A French population-based study[J]. Hepatology, 2002, 36(2): 451-455. DOI: 10.1053/jhep.2002.34857.
    [6]
    JICK H, DERBY LE, GARCíA RODRÍGUEZ LA, et al. Liver disease associated with diclofenac, naproxen, and piroxicam[J]. Pharmacotherapy, 1992, 12(3): 207-212.
    [7]
    DERBY LE, JICK H, HENRY DA, et al. Cholestatic hepatitis associated with flucloxacillin[J]. Med J Aust, 1993, 158(9): 596-600. DOI: 10.5694/j.1326-5377.1993.tb137624.x.
    [8]
    DERBY LE, JICK H, HENRY DA, et al. Erythromycin-associated cholestatic hepatitis[J]. Med J Aust, 1993, 158(9): 600-602. DOI: 10.5694/j.1326-5377.1993.tb137625.x.
    [9]
    GARCÍA RODRÍGUEZ LA, STRICKER BH, ZIMMERMAN HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid[J]. Arch Intern Med, 1996, 156(12): 1327-1332. DOI: 10.1001/archinte.1996.00440110099013.
    [10]
    GARCÍA RODRÍGUEZ LA, WALLANDER MA, STRICKER BH. The risk of acute liver injury associated with cimetidine and other acid-suppressing anti-ulcer drugs[J]. Br J Clin Pharmacol, 1997, 43(2): 183-188. DOI: 10.1046/j.1365-2125.1997.05268.x.
    [11]
    JICK H, DERBY LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity[J]. Pharmacotherapy, 1995, 15(4): 428-432.
    [12]
    DERBY LE, GUTTHANN SP, JICK H, et al. Liver disorders in patients receiving chlorpromazine or isoniazid[J]. Pharmacotherapy, 1993, 13(4): 353-358.
    [13]
    GARCÍA RODRÍGUEZ LA, WILLIAMS R, DERBY LE, et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors[J]. Arch Intern Med, 1994, 154(3): 311-316. DOI: 10.1001/archinte.1994.00420030117012.
    [14]
    de ABAJO FJ, MONTERO D, MADURGA M, et al. Acute and clinically relevant drug-induced liver injury: A population based case-control study[J]. Br J Clin Pharmacol, 2004, 58(1): 71-80. DOI: 10.1111/j.1365-2125.2004.02133.x.
    [15]
    VEGA M, VERMA M, BESWICK D, et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: Preliminary findings from gastroenterologist-based surveillance in the population of the state of delaware[J]. Drug Saf, 2017, 40(9): 783-787. DOI: 10.1007/s40264-017-0547-9.
    [16]
    AISO M, TAKIKAWA H, TSUJI K, et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan[J]. Hepatol Res, 2019, 49(1): 105-110. DOI: 10.1111/hepr.13288.
    [17]
    BAGHERI H, MICHEL F, LAPEYRE-MESTRE M, et al. Detection and incidence of drug-induced liver injuries in hospital: A prospective analysis from laboratory signals[J]. Br J Clin Pharmacol, 2000, 50(5): 479-484. DOI: 10.1046/j.1365-2125.2000.00282.x.
    [18]
    MEIER Y, CAVALLARO M, ROOS M, et al. Incidence of drug-induced liver injury in medical inpatients[J]. Eur J Clin Pharmacol, 2005, 61(2): 135-143. DOI: 10.1007/s00228-004-0888-z.
    [19]
    CANO-PANIAGUA A, AMARILES P, ANGULO N, et al. Epidemiology of drug-induced liver injury in a University Hospital from Colombia: Updated RUCAM being used for prospective causality assessment[J]. Ann Hepatol, 2019, 18(3): 501-507. DOI: 10.1016/j.aohep.2018.11.008.
    [20]
    SUK KT, KIM DJ, KIM CH, et al. A prospective nationwide study of drug-induced liver injury in Korea[J]. Am J Gastroenterol, 2012, 107(9): 1380-1387. DOI: 10.1038/ajg.2012.138.
    [21]
    SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11. DOI: 10.1053/j.gastro.2019.02.002.
    [22]
    de VALLE MB, AV KLINTEBERG V, ALEM N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic[J]. Aliment Pharmacol Ther, 2006, 24(8): 1187-1195. DOI: 10.1111/j.1365-2036.2006.03117.x.
    [23]
    BJÖRNSSON E, ISMAEL S, NEJDET S, et al. Severe jaundice in Sweden in the new millennium: Causes, investigations, treatment and prognosis[J]. Scand J Gastroenterol, 2003, 38(1): 86-94. DOI: 10.1080/00365520310000492.
    [24]
    VUPPALANCHI R, LIANGPUNSAKUL S, CHALASANI N. Etiology of new-onset jaundice: How often is it caused by idiosyncratic drug-induced liver injury in the United States?[J]. Am J Gastroenterol, 2007, 102(3): 558-562; quiz 693. DOI: 10.1111/j.1572-0241.2006.01019.x.
    [25]
    WEI G, BERGQUIST A, BROOMÉ U, et al. Acute liver failure in Sweden: Etiology and outcome[J]. J Intern Med, 2007, 262(3): 393-401. DOI: 10.1111/j.1365-2796.2007.01818.x.
    [26]
    OSTAPOWICZ G, FONTANA RJ, SCHIØDT FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States[J]. Ann Intern Med, 2002, 137(12): 947-954. DOI: 10.7326/0003-4819-137-12-200212170-00007.
    [27]
    REUBEN A, KOCH DG, LEE WM. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study[J]. Hepatology, 2010, 52(6): 2065-2076. DOI: 10.1002/hep.23937.
    [28]
    GOLDBERG DS, FORDE KA, CARBONARI DM, et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system[J]. Gastroenterology, 2015, 148(7): 1353-1361. e3. DOI: 10.1053/j.gastro.2015.02.050.
    [29]
    GARCÍA RODRÍGUEZ LA, RUIGÓMEZ A, JICK H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom[J]. Pharmacotherapy, 1997, 17(4): 721-728.
    [30]
    CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study[J]. Gastroenterology, 2015, 148(7): 1340-1352. e7. DOI: 10.1053/j.gastro.2015.03.006.
    [31]
    DEVARBHAVI H, DIERKHISING R, KREMERS WK, et al. Single-center experience with drug-induced liver injury from India: Causes, outcome, prognosis, and predictors of mortality[J]. Am J Gastroenterol, 2010, 105(11): 2396-2404. DOI: 10.1038/ajg.2010.287.
    [32]
    NAVARRO VJ, BARNHART H, BONKOVSKY HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network[J]. Hepatology, 2014, 60(4): 1399-1408. DOI: 10.1002/hep.27317.
    [33]
    TESCHKE R, EICKHOFF A. Herbal hepatotoxicity in traditional and modern medicine: Actual key issues and new encouraging steps[J]. Front Pharmacol, 2015, 6: 72. DOI: 10.3389/fphar.2015.00072.
    [34]
    HELMY A. Review article: Updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome[J]. Aliment Pharmacol Ther, 2006, 23(1): 11-25. DOI: 10.1111/j.1365-2036.2006.02742.x.
    [35]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. DOI: 10.1016/j.jhep.2019.02.014.
    [36]
    LUCENA MI, ANDRADE RJ, FERNÁNDEZ MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain[J]. Hepatology, 2006, 44(4): 850-856. DOI: 10.1002/hep.21324.
    [37]
    LUCENA MI, ANDRADE RJ, KAPLOWITZ N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex[J]. Hepatology, 2009, 49(6): 2001-2009. DOI: 10.1002/hep.22895.
    [38]
    MOLLESTON JP, FONTANA RJ, LOPEZ MJ, et al. Characteristics of idiosyncratic drug-induced liver injury in children: Results from the DILIN prospective study[J]. J Pediatr Gastroenterol Nutr, 2011, 53(2): 182-189. DOI: 10.1097/MPG.0b013e31821d6cfd.
    [39]
    CHALASANI N, FONTANA RJ, BONKOVSKY HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States[J]. Gastroenterology, 2008, 135(6): 1924-1934, 1934. e1-4. DOI: 10.1053/j.gastro.2008.09.011.
    [40]
    LARREY D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver[J]. Semin Liver Dis, 2002, 22(2): 145-155. DOI: 10.1055/s-2002-30105.
    [41]
    ANDRADE RJ, LUCENA MI, FERNÁNDEZ MC, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period[J]. Gastroenterology, 2005, 129(2): 512-521. DOI: 10.1016/j.gastro.2005.05.006.
    [42]
    ORTEGA-ALONSO A, STEPHENS C, LUCENA MI, et al. Case characterization, clinical features and risk factors in drug-induced liver injury[J]. Int J Mol Sci, 2016, 17(5). DOI: 10.3390/ijms17050714.
    [43]
    DEVARBHAVI H. An update on drug-induced liver injury[J]. J Clin Exp Hepatol, 2012, 2(3): 247-259. DOI: 10.1016/j.jceh.2012.05.002.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1440) PDF downloads(384) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return